Evaluating the research-grade Bronchogen DNA stabilizer price requires understanding synthesis standards, purity verification tiers, and analytical testing necessary for reproducible in vitro assays. Bronchogen is a synthetic short peptide studied for its capacity to interact with DNA chromatin and modulate gene expression in respiratory tissue models. PX1 Research provides high-purity, USA-manufactured research compounds accompanied by lot-specific certificates of analysis to support rigorous scientific investigation.
Evaluating the research-grade Bronchogen DNA stabilizer price requires understanding synthesis standards, purity verification tiers, and analytical testing necessary for reproducible in vitro assays. Bronchogen is a synthetic short peptide studied for its capacity to interact with DNA chromatin and modulate gene expression in respiratory tissue models. PX1 Research provides high-purity, USA-manufactured research compounds accompanied by lot-specific certificates of analysis to support rigorous scientific investigation.
The price of research-grade Bronchogen is primarily determined by mass quantity (typically 10 mg to 50 mg analytical vials), chemical purity level (minimum 98% validated via RP-HPLC), and analytical certification thoroughness including mass spectrometry and endotoxin testing. High-purity Bronchogen manufactured under strict USA quality controls reflects the cost of rigorous third-party ISO 17025 laboratory verification.
When purchasing compounds for genomic or cellular assays, price per milligram should always be evaluated alongside analytical transparently. Inexpensive options frequently lack lot-specific documentation or fail sequence verification, introducing uncontrolled variables into experimental systems. PX1 Research maintains competitive institutional pricing while guaranteeing that every vial of Bronchogen 10mg is batch-tested for purity, identity, and heavy metal contaminants.
Bronchogen is a synthetic tetrapeptide comprised of the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). It belongs to a class of short bioregulatory peptides originally conceptualized to mimic endogenous peptide signaling in specific tissue matrices. In structural biology research, small peptide chains of this length are investigated for their ability to cross nuclear membranes and interact directly with double-stranded DNA.
Preclinical studies suggest that short peptides like Bronchogen bind to specific complementary sequences within histone proteins and DNA promoter regions. Through sequence-specific binding, the peptide is hypothesized to alter chromatin condensation levels, potentially facilitating transcription factor access to silenced or downregulated genes. Investigators exploring genomic stability analyze these interactions using electrophoretic mobility shift assays (EMSA) and circular dichroism spectroscopy. For broader context on peptide-chromatin interaction models, explore our comprehensive research library hub.
In vitro data indicate that Bronchogen administration in cultured bronchial epithelial cell lines influences the expression of proteins responsible for cell structure integrity and antioxidant defense. Researchers evaluating cellular senescence have observed that treatment with short peptide bioregulators can suppress markers of hyper-inflammation and reduce DNA strand break accumulation following exposure to oxidative stress agents.
Animal studies examining lung tissue homeostatic response have reported that Bronchogen modulates cytokine signaling pathways, specifically downregulating pro-inflammatory markers such as TNF-alpha and IL-6 in rodent models of acute airway irritation. Additionally, preclinical findings suggest a potential protective effect on genomic stability within pulmonary fibroblasts subjected to environmental stressors. Researchers can browse our catalog of all research peptides to identify complimentary reagents for cellular stress response assays.
Evaluating the true value of a research compound extends beyond the surface-level unit cost. Purchasing low-cost peptides without verified analytical testing risks introducing synthesis byproducts, truncated peptide sequences, or residual TFA (trifluoroacetic acid) salts that alter cell viability assays and obscure experimental outcomes.
To ensure experimental validity, research laboratories should verify four core analytical metrics before procuring Bronchogen: reverse-phase high-performance liquid chromatography (RP-HPLC) showing ≥98% purity, electrospray ionization mass spectrometry (ESI-MS) confirming molecular weight, quantitative endotoxin testing maintaining levels below 0.5 EU/mg, and lot-traceable documentation. Facilitating volume-based procurement for institutional facilities, PX1 Research offers structured supply agreements through our wholesale lab portal.
Bronchogen is frequently analyzed alongside other short peptide bioregulators developed to evaluate gene expression and tissue integrity. While Bronchogen primarily targets respiratory tissue models and chromatin accessibility, related compounds possess distinct target profiles and amino acid sequences.
For instance, Epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide widely studied for its interactions with telomerase activity and circadian rhythm regulation in pineal tissue cultures. Similarly, Thymogen (Glu-Trp) is a dipeptide evaluated primarily in immunological cellular models, whereas Chonluten (Glu-Asp-Gly) shares structural commonalities with Bronchogen but exhibits distinct binding affinities in respiratory and mucosal tissue assays. Comparing these structural analogues helps researchers elucidate how minor amino acid substitutions influence peptide-DNA binding kinetics.
Bronchogen is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and storage. Proper reconstitution in a sterile laboratory environment is essential to preserve peptide integrity and prevent premature degradation.
For standard in vitro applications, lyophilized Bronchogen should be reconstituted using sterile laboratory-grade water or phosphate-buffered saline (PBS, pH 7.4). Avoid vigorous vortexing or mechanical agitation, as shear forces can disrupt peptide solution homogeny; gentle vial rotation is recommended. If long-term aqueous storage is required, reconstituting with a small percentage of bacteriostatic agent or working in sterile aliquots prevents microbial growth in culture media preparations.
Lyophilized Bronchogen should be stored at -20°C upon receipt for short-to-medium term storage, or at -80°C for extended stability exceeding 24 months. Vials should be kept in a desiccated container to protect against atmospheric moisture absorption prior to initial opening.
Once reconstituted into aqueous solution, Bronchogen stock solutions should be divided into single-use aliquots to prevent repeated freeze-thaw cycles, which accelerate peptide bond hydrolysis. Reconstituted aliquots remain stable at 4°C for up to 7 days, or at -20°C for up to 90 days. Always allow lyophilized vials to reach room temperature inside a desiccator before reconstitution to prevent condensation accumulation on the peptide cake.
PX1 Research provides high-purity Bronchogen synthesized in USA-based, GMP-compliant facilities. Every batch undergoes rigorous quality control to verify sequence fidelity, identity, chemical purity, and endotoxin thresholds via third-party ISO 17025 accredited analytical laboratories.
Orders ship same-day (Monday through Friday) from our centralized distribution facilities in California and Arizona, ensuring rapid transit to maintain product stability. Each shipment includes lot-specific Certificates of Analysis (COA) detailing RP-HPLC chromatograms and mass spectrometry data. Laboratory managers seeking reliable supply chains for advanced DNA repair and bioregulatory peptide studies can depend on PX1 Research for batch consistency and transparent verification.
What determines the price of research-grade Bronchogen?
Bronchogen pricing is determined by synthesis purity (minimum 98%), batch size, third-party analytical testing (RP-HPLC and ESI-MS), endotoxin screening, and USA manufacturing standards.
What is the amino acid sequence of Bronchogen?
Bronchogen is a synthetic tetrapeptide with the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu).
Is Bronchogen approved for human clinical use?
No. Bronchogen is supplied strictly as a research compound for in vitro laboratory experiments, cellular assays, and preclinical research models. It is not for human or veterinary consumption.
How should lyophilized Bronchogen be stored?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment protected from light. Prior to opening, vials should reach room temperature to avoid moisture condensation.
What liquid should be used to reconstitute Bronchogen for in vitro assays?
For cell culture and biochemical assays, reconstitute Bronchogen using sterile laboratory water, sterile 0.9% saline, or phosphate-buffered saline (PBS, pH 7.4).
How does PX1 Research verify Bronchogen purity?
PX1 Research verifies every batch through an independent ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity and Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence confirmation.
What endotoxin levels are acceptable for research-grade Bronchogen?
High-quality research-grade peptides should maintain endotoxin levels below 0.5 EU/mg (and ideally <0.1 EU/mg) to prevent non-specific inflammatory signaling in cell culture models.
Can Bronchogen stock solution undergo multiple freeze-thaw cycles?
Multiple freeze-thaw cycles should be avoided as they degrade peptide structure. Reconstituted stock solutions should be divided into single-use aliquots and stored at -20°C.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.